Actionable news
0
All posts from Actionable news
Actionable news in CLLS: Cellectis SA,

InPlay from Briefing.com

7:55 am Ipsen S.A. reports Q3, reaffirms 2015 outlook (IPSEY) :

  • The co reported Q3 revenue growth of +5.2% to 354.5 million

Ipsen confirms its 2015 objectives:

  • Specialty care sales growth at or above 14.0% year-on-year
  • Primary care sales decline between -3.0% and 0.0% year-on-year
  • Core Operating margin at or above 22.0% of Group sales

7:55 am S&P futures vs fair value: -9.20. Nasdaq futures vs fair value: -24.40. (:WRAPX) :

U.S. equity futures trade near their pre-market lows amid cautious action overseas. The S&P 500 futures hover nine points below fair value after a steady retreat from their overnight highs.

Meanwhile, Treasuries hold slim losses with the 10-yr yield up one basis point at 2.10%.

On the economic front, weekly Initial Claims (Briefing.com consensus 264,000) and the advance reading of Q3 GDP (consensus 1.6%) will be released at 8:30 ET while the September Pending Home Sales report (expected 0.6%) will cross the wires at 10:00 ET.

In U.S. corporate news of note:

  • Deutsche Bank (DB 28.35, -1.96): -6.5% after announcing a EUR6 billion loss in the third quarter combined with news of upcoming layoffs for 9,000 full time employees and 6,000 contractors.
  • Amgen (AMGN 164.20, +1.53): +0.9% after beating earnings/revenue estimates and raising its guidance.
  • Royal Dutch Shell (RDS.A 51.92, -1.10): -2.1% in reaction to a bottom-line miss on above-consensus revenue.
  • STMicroelectronics (STM 6.78, -0.43): -6.0% after cautious guidance overshadowed a bottom-line beat.
  • NXP Semiconductor (NXPI 79.00, -11.92): -13.1% after below-consensus revenue overshadowed a bottom-line beat and an expanded buyback.
  • Altria Group (MO 62.00, +0.56): +0.9% after reporting a one-cent miss on above-consensus revenue.
  • Aetna (AET 117.80, +6.69): +6.0% after beating earnings estimates on light revenue.
  • Buffalo Wild Wings (BWLD 157.00, -27.40): -14.9% after missing estimates and lowering its fiscal-year 2015 guidance.
  • GoPro (GPRO 24.70, -5.51): -18.2% after missing on both metrics and issuing defensive guidance.
  • Yelp (YELP 23.00, +0.93): +4.2% after better than expected revenue and revenue guidance overshadowed a bottom-line miss.

Reviewing overnight developments:

  • Asian markets ended mixed. Japan's Nikkei +0.2%, Hong Kong's Hang Seng -0.6%, and China's Shanghai Composite +0.4%
    • In economic data:
      • Japan's September Industrial Production +1.0% month-over-month (expected -0.5%; prior -1.2%)
      • Australia's September HIA New Home Sales -4.0% (prior +2.3%), Q3 Export Price Index 0.0% quarter-over-quarter (expected +0.5%; prior -4.4%), and Q3 Import Price Index +1.4% quarter-over-quarter (expected +1.6%; prior +1.4%)
      • Singapore's Q3 Unemployment Rate 2.0% (expected 2.0%; prior 2.0%)
    • In news:
      • The Reserve Bank of New Zealand left its official cash rate at 2.75%, as expected
  • Major European indices trade in negative territory. Germany's DAX -0.4%, France's CAC -0.9%, and UK's FTSE -1.1%. Elsewhere, Italy's MIB -0.9% and Spain's IBEX -0.8%
    • Economic data was plentiful:
      • Eurozone October Business and Consumer Survey ticked up to 105.9 from 105.6 (expected 105.2)
      • UK's September BoE Consumer Credit GBP1.261 billion (expected GBP1.10 billion; prior GBP1.263 billion) and Mortgage Lending GBP3.60 billion (consensus GBP3.50 billion; previous GBP3.40 billion). Separately, October CBI Distributive Trades Survey fell to 19 from 49 (expected 35) and Nationwide HPI 0.6% month-over-month (expected 0.5%; prior 0.5%)
      • Germany's October Unemployment Change -5,000 (expected -4,000; prior 1,000) while the Unemployment Rate held at 6.4%, as expected
      • Spain's September Retail Sales +4.3% year-over-year (consensus 3.0%; prior 3.0%) and October CPI +0.7% month-over-month, as expected; -0.7% year-over-year (consensus -0.6%)
    • Among news of note:
      • Riksbank Governor Stefan Ingves said the central bank could continue cutting its benchmark rate, going below -0.35% if needed. Mr. Ingves also noted that he sees significant risks in rising debt levels.

7:54 am On the Wires (:WIRES) :

  • One Horizon Group (OHGI) announced that its Aishuo App has achieved over 10 million downloads since its launch in late February 2015, and is well on the way to reaching its 24 month stated goal of 15 million users
  • Imprimis Pharmaceuticals (IMMY) announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. FDA as a 503B sterile outsourcing facility under the Drug Quality and Security Act of 2013

7:53 am Corning announces $1.25 bln accelerated share repurchase; expected to completed 1Q16 (GLW) :

The ASR is executed pursuant to the $2 bln share repurchase program authorized by Co's BOD on July 15, 2015, which was supplemented by an additional $4 bln share repurchase program authorized on October 26, 2015.

  • Under the terms of the ASR, Corning has agreed to repurchase in total $1.25 bln of its common stock from Morgan Stanley & Co. LLC, with an initial delivery of ~53.1M shares based on current market prices.
  • The program is expected to be completed in 1Q16.
  • Co expects to finance the ASR with cash on hand.

7:52 am China Telecom reports YTD results, revenue up 1.1% YoY (CHA) : Co reports earnings results for the nine months ended Sep 30 in a 6-K filing. Profit increased 1.2% YoY to RMB16,407 mln. Revenue rose 1.1% YoY to RMB246, 317 mln. There are no analyst estimates. Mobile subscribers were 194.34 mln at Sep 30 vs 181.57 mln last year.

7:51 am Swiss Re reports YTD results (SSREY) :

  • Group 9M 2015 net income increased 12% to USD 3.7 billion; benefiting from strong underwriting and investment result, benign natural catastrophe experience
  • Swiss Re estimates claims burden from the Tianjin explosion to be ~ USD 250 million
  • Swiss Re plans to start share buy-back programme in mid-November; subject to regulatory approval
  • Swiss Re Board of Directors proposes Sir Paul Tucker for election at the upcoming AGM in April 2016

7:49 am Overnight Treasury Summary (BONDX) :

FOMC Statement Puts December Rate Hike Firmly on the Table

  • The U.S. Treasury market is little-changed overnight after the FOMC statement released on Wednesday showed that the committee has confidence in U.S. economic growth and may well raise rates at the December meeting. The news sent yields higher, particularly at the front end and belly of the yield curve, and fed fund futures are now indicating a 46% chance for December liftoff versus 34% yesterday. Overnight, price data from Germany and Spain showed that deflation may be subsiding and Japanese industrial production beat estimates ahead of the BoJ meeting Friday. The U.S. Dollar Index has given back some of its post FOMC gains, now trading down 0.40% to 97.39, and the S&P 500 futures are indicating an open down 0.42% to 2,081.6. This morning, we will see the advance estimate for Q3 GDP which the Briefing.com consensus expects to be 1.6%
  • Yield Check:
    • 2-yr: +2 bps to 0.72%
    • 5-yr: unch at 1.48%
    • 10-yr: unch at 2.10%
    • 30-yr: unch at 2.88%
  • International News:
    • In the U.K., the Nationwide Housing Price Index rose 3.9% in the year to October, better than both expectations and the September reading of 3.8%
    • Spain's consumer price index fell 0.7% y/y in October according to the preliminary estimate. October's was a steeper decline than expected, but better than the 0.9% drop in September
      • Spain's harmonized index of consumer prices fell 0.9% in the year to October, in line with expectations
    • The number of Germans without jobs declined by 5K in October, better than expected. The rolls of the unemployed grew by 1K in September
      • The regions of Germany reported inflation data today and deflation has ended on a monthly basis in Bavaria and Hesse. Price data for all of Germany will be released at 09:00 ET
    • Japanese industrial production climbed 1.0% m/m in September according to preliminary data, better than the expectations for a decline. Industrial production fell 1.2% in August
      • The forecast for growth in October was 4.1%, according to a survey that is part of the report
      • The Bank of Japan meets on Friday and this positive surprise muddles the prospects for additional easing, which economists currently see as a toss-up
    • In Australia, the Housing Industry Association reported that new home sales fell 4.0% m/m in September after rising 2.3% in August
    • The Chinese government announced that it will end the one-child policy
  • Data Out Today:
    • Initial Jobless Claims for the week ending 10/24 and Continuing Jobless Claims for the week ending 10/17 (08:30 ET)
    • Q3 GDP and Chain Deflator -- Advanced Estimate (08:30 ET)
    • September Pending Home Sales (10:00 ET)
    • Natural Gas Inventories for the week ending 10/24 (10:30 ET)
  • Treasury Auction:
    • $29 bln 7-year note auction (results at 13:00 ET)

7:48 am Boeing and AL Israel Airlines agree to an order of up to nine 787 Dreamliners, valued at more than $2.2 bln (BA) : Three of the orders will be added to co's Orders & Deliveries website on Nov. 5 and the remainder will be posted as further contractual requirements are finalized.

7:48 am Brunswick beats by $0.03, reports revs in-line; guides FY15 in-line (BC) :

  • Reports Q3 (Sep) earnings of $0.77 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.74; revenues rose 6.4% year/year to $991.9 mln vs the $994.03 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $2.80-2.85 vs. $2.84 Capital IQ Consensus Estimate; sees FY15 revs up +7% (approximately $4.11 bln) vs. $4.12 bln Capital IQ Consensus Estimate.
  • "Our top line reflected strong growth rates in fiberglass outboard and sterndrive/inboard boats. This growth also included a solid performance by marine parts and accessories, outboard engines, fitness equipment and aluminum boats. Sales growth was driven by solid market demand, higher average marine selling prices and continued market share gains... strong earnings growth was also supported by a more favorable product mix, benefits from cost reductions and savings related to sourcing initiatives, partially offset by the unfavorable effects of foreign exchange,"

7:48 am Commodities start the day off lower despite weakness seen in dollar index; oil, copper, precious metals are all in the red (:COMDX) :

  • Commodities, as measured by the Bloomberg Commodity Index, are trading -0.7%
  • This morning, the dollar index is lower, which isn't doing much for commodities
    • The index is now -0.4% at 97.40
  • Gold and silver futures have been in the red all day so far, including the overnight session, led by silver
    • Dec gold is now -1.7% at $1156.40/oz, while Dec silver is -2.7% at $15.86/oz
    • Dec copper is -1.2% at $2.34/lb
  • In energy, natural gas futures are trading higher ahead of the weekly EIA storage data
  • Dec nat gas is currently +1.4% at $2.33/MMBtu
  • Oil, on the other hand, is trading near today's low, currently -1.4% at $45.28/barrel

7:48 am Ultra Petroleum beats by $0.04, misses on revs (UPL) :

  • Reports Q3 (Sep) earnings of $0.21 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.17; revenues fell 22.9% year/year to $222.5 mln vs the $255.2 mln Capital IQ Consensus.
  • The company is increasing full-year 2015 production guidance to 288 -- 292 Bcfe from the previous range of 283 -- 290 Bcfe while reaffirming its $500.0 mln capital investment program
  • In the fourth quarter of 2015, the company's realized natural gas price is expected to average 0-2?low the NYMEX price due to differentials, before consideration of any hedging activity.
  • Realized Q4 pricing for oil and condensate is expected to be about 15-18% below the average NYMEX price, before consideration of any hedging activity.

7:41 am Resolute Forest Products beats by $0.06; Revenue decreased 17% y/y (RFP) :

  • Reports Q3 (Sep) earnings of $0.15 per share, $0.06 better than the two analyst estimate of $0.09. Revenue decreased 17.4% y/y to $905 mln, no analyst estimates.
  • Q3 adjusted EBITDA of $82 million.
  • Outlook: "Third quarter realized lumber prices dropped to levels not seen since the first quarter of 2012 before bottoming out in September and starting to recover in October. Markets continue to reflect lower North American lumber exports to Asia, but it appears that the mid-October expiration of the Canada-U.S. Softwood Lumber Agreement is not having a significant impact on supply so far... The accelerating pace of demand decline in North America and the increase of currency-driven imports will continue to play a role in specialty papers markets in North America, with additional uncertainty resulting from the market access hurdles imposed by the U.S. Department of Commerce in connection with its investigation of imports of supercalendered papers from Canada. Consumption of newsprint shows no sign of improvement, but we still expect to run all of our newsprint machines..."

7:40 am Enpro Industries beats by $0.03, reports revs in-line; announces $50 mln repurchase program (NPO) :

Reports Q3 (Sep) earnings of $0.51 per share, $0.03 better than the Capital IQ Consensus of $0.48; revenues rose 1.3% year/year to $306.6 mln vs the $306.15 mln two analyst estimate.

  • "Market conditions remain soft, and global economic volatility and sluggish oil and gas markets have resulted in lower demand levels in several of our businesses. We have sound demand levels in the nuclear, petrochemical, and engine parts and service markets. However, softer conditions in many of our other markets and the strong dollar continue to affect our results. Given these ongoing market headwinds and our results for the quarter, we expect segment profit for the year to be at, or slightly below the low end of the guidance previously provided, excluding the impact of additional restructuring charges expected in the fourth quarter of 2015. We estimate restructuring charges for the year to be in the range of $10.0 to $13.0 million compared to the $3.2 million included in our previous guidance. We expect GST's results to be within the range previously provided. This revised guidance is based on exchange rates in effect at the end of the third quarter. Despite current challenging market conditions, longer term, we expect continued benefits from our strategic growth initiatives including growth from recent and future strategic acquisitions and continued emphasis on improving operational efficiencies,"
  • The Board of Directors approved a new program authorizing the company to repurchase up to $50.0 million of its common shares.

7:38 am SCANA Corp beats by $0.07, misses on revs; reaffirms FY15 EPS guidance; guides FY16 EPS above consensus (SCG) :

  • Reports Q3 (Sep) earnings of $1.04 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.97; revenues fell 4.7% year/year to $1.07 bln vs the $1.14 bln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees EPS of $3.60-3.80, excluding non-recurring items, vs. $3.73 Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY16, sees EPS of $3.90-4.10, excluding non-recurring items, vs. $3.88 Capital IQ Consensus Estimate.

7:38 am Zimmer Biomet beats by $0.08, reports revs in-line; guides FY15 EPS above consensus; reinstates its share repurchase program (ZBH) :

  • Reports Q3 (Sep) earnings of $1.64 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $1.56; revenues rose 59.3% year/year to $1.76 bln vs the $1.76 bln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees EPS of $6.83-6.87, excluding non-recurring items, vs. $6.76 Capital IQ Consensus Estimate and vs prior guidance of $6.65-6.80. Co slightly lowers its constant currency revenue guidance to +1.0-1.5% from +1.5-2.0%. This is not comparable to consensus which is not constant currency.
  • Co reinstates its share repurchase program. The existing program was temporarily suspended in April 2014 in anticipation of the Biomet transaction. Currently, $599.5 mln of share repurchase authorization remains available under this program.

7:38 am EMCOR Group misses by $0.05, beats on revs; guides FY15 EPS below consensus, revs in-line; to repurchase up to an additional $200 million (EME) :

  • Reports Q3 (Sep) earnings of $0.66 per share, $0.05 worse than the Capital IQ Consensus of $0.71; revenues rose 8.5% year/year to $1.7 bln vs the $1.64 bln Capital IQ Consensus.
  • Co issues guidance for FY15, sees EPS of $2.65-2.75 vs. $2.78 Capital IQ Consensus Estimate; sees FY15 revs of $6.6-6.7 bln vs. $6.63 bln Capital IQ Consensus Estimate.
  • The Company also announced today that its Board of Directors has authorized a new share repurchase program for the Company to repurchase up to an additional $200 mln of its outstanding common stock.

7:38 am Coca-Cola Ent beats by $0.03, misses on revs; updates FY15 guidance (CCE) :

  • Reports Q3 (Sep) earnings of $0.84 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.81; revenues fell 14.7% year/year to $1.82 bln vs the $1.87 bln Capital IQ Consensus.
  • For 2015, CCE continues to expect diluted earnings per share to grow at the upper end of the range of 6 percent to 8 percent on a comparable and currency-neutral basis. Based on recent rates, currency translation would negatively impact full-year 2015 diluted earnings per share by approximately 18 percent. Operating income is expected to achieve slightly positive growth, while net sales growth is now expected to be flat to slightly negative, both on a comparable and currency-neutral basis. The company expects 2015 free cash flow in a range of $600 million to $650 million including the expected negative impact of currency translation based on recent rates. Capital expenditures are expected to be approximately $325 million.

7:38 am MiMedx Group reports EPS in-line, revs in-line; guides Q4 revs in-line (MDXG) :

  • Reports Q3 (Sep) earnings of $0.06 per share, in-line with the Capital IQ Consensus of $0.06; revenues rose 46.3% year/year to $49 mln vs the $49.01 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $49.5-52.5 mln vs. $51.50 mln Capital IQ Consensus Estimate.
  • The co provided guidance for fourth quarter of 2015 operating profit margin to be in the range of 14% to 15%. The co also narrowed its previously published guidance for full year 2015 operating profit margin to be in the range of 12% to 13%.

7:36 am Ally Financial reports EPS in-line (ALLY) :

  • Reports Q3 (Sep) earnings of $0.51 per share, in-line with the Capital IQ Consensus of $0.51.
  • Improved net financing revenue, excluding original issue discount (:OID), continued to drive strong results and totaled $981 million in the third quarter of 2015, up from $936 million a year ago.
  • Revenue from retail auto loan growth more than offset a decline in net lease revenue. Consumer auto originations remained robust at $11.1 billion for the quarter, increasing from $10.8 billion last quarter and down from $11.8 billion in the same period last year, with the company on track to exceed its originations target in the high $30 billions for 2015.

7:35 am CMS Energy beats by $0.03, misses on revs; raised the low end of its 2015 adjusted EPS guidance, in-line (CMS) :

  • Reports Q3 (Sep) earnings of $0.53 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.50; revenues rose 3.9% year/year to $1.49 bln vs the $1.55 bln Capital IQ Consensus.
  • CMS Energy raised the low end of its 2015 adjusted EPS guidance to $1.87-1.89, excluding non-recurring items, vs. $1.88 Capital IQ Consensus Estimate, up from $1.86-1.89, consistent with performance at the high end of its long-term plan to grow earnings per share at 5% to 7%.
  • The co expects to double investments in its gas business over the next decade.
  • Those investments include expansion of its pipeline and storage system, adding new customers who formerly used higher-cost propane, and strengthening pipeline integrity in a multi-year line replacement program

7:34 am FTI Consulting misses by $0.01, misses on revs; lowers FY15 guidance (FCN) :

  • Reports Q3 (Sep) adj earnings of $0.53 per share, $0.01 worse than the Capital IQ Consensus of $0.54; revenues rose 1.0% year/year to $455.5 mln vs the $460.61 mln Capital IQ Consensus. Gross profit grew 32% to $5.9 million from $4.5 million for the third quarter a year ago.
  • Co issues lowered guidance for FY15, sees EPS of $1.80-1.95 from $1.95-2.15 vs. $2.08 Capital IQ Consensus Estimate; lowers FY15 revs to $1.74-1.78 bln from $1.75-1.85 bln vs. $1.79 bln Capital IQ Consensus Estimate.

7:34 am McKesson reports Q2 (Sep) results, beats on revs; guides FY16 EPS in-line; announces new $2 bln share repurchase program (MCK) :

  • Reports Q2 (Sep) earnings of $3.31 per share, may not be comparable to the Capital IQ Consensus of $2.99; revenues rose 10.4% year/year to $48.76 bln vs the $47.8 bln Capital IQ Consensus. Second-quarter results include a pre-tax gain of $51 million, or 14 cents per diluted share, related to the sale of the ZEE Medical business within the Distribution Solutions segment. Second-quarter results also reflect lower than expected tax expense driven by a discrete tax benefit of $25 million, or 11 cents per diluted share.
  • Co issues in-line guidance for FY16, sees EPS of $12.50-13.00 vs. $12.68 Capital IQ Consensus Estimate.
  • Board of Directors authorized a new $2 billion share repurchase program.

7:33 am Marinus Pharmaceuticals initiates the clinical phase of its IV ganaxolone program in Status Epilepticus after preclinical studies yielded positive results (MRNS) :

Co initiates the clinical phase of its IV ganaxolone program in Status Epilepticus after preclinical studies yielded positive results and supported advancement to human trials.

  • Ganaxolone IV promoted survival and showed better or comparable reversal of seizures than the endogenous neurosteroid, allopregnanolone, in clinically translatable rodent models of SE.
  • Co will commence a Phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetics of ganaxolone IV before initiating a clinical trial in SE patients later in 2016.

7:31 am Astoria Fincl to be acquired by New York Community (NYCB) for $19.66/share in a $2 bln deal; expected to be immediately accretive to pro forma diluted EPS and pro forma tangible BV/share (AF) :

New York Community Bancorp, (NYCB) and Astoria Financial Corporation sign a definitive agreement under which the two companies will combine in a strategic merger. The transaction, which is valued at ~$2.0 billion, is expected to be immediately accretive to pro forma diluted EPS and pro forma tangible BV/share.Pending receipt of the necessary shareholder and regulatory approvals, the merger is currently expected to be completed in 4Q16.

  • Shareholders of Astoria will receive one share of New York Community common stock and $0.50 in cash in exchange for each share of Astoria stock held at the merger date. With the exception of the cash component, the transaction is tax-free to Astoria's investors. Based on New York Community's closing price of $19.16 per share on October 28, 2015, the merger will result in each Astoria share being valued at $19.66.
  • The combined company, on a pro forma basis, will have 241 banking offices in Metro New York, including all five boroughs of New York City, Long Island, and Westchester County. Including New York Community's 115 branches in Ohio, Arizona, Florida, and New Jersey, the combined company will have more than 350 branch offices and pro forma deposits of approximately $37.3 billion.
  • Under the agreement and plan of merger, Joseph R. Ficalora will continue to serve as President and CEO of the combined company. Monte N. Redman, President and CEO of Astoria and Astoria Bank, and Ralph Palleschi, Astoria's Chairman, will become members of the BOD of New York Community and its bank subsidiaries.

7:31 am Lake Share Gold misses by $0.01 (LSG) :

Reports Q3 (Sep) adj. loss of ($0.01) per share, $0.01 worse than the Capital IQ Consensus of $0.00; revenues fell 0.1% year/year to $63.05 mln vs the $63.1 mln Capital IQ Consensus.

  • Co reported all-in sustaining costs of US$845 (US$924 in Q3/15)

Looking ahead:

  • The co remains on track to achieve its production and unit cost targets in 2015.
  • These targets include production for the full year of at least 180,000 ounces, cash operating costs per ounce sold of better than US$650 and all-in sustaining costs below US$950 per ounce sold.
  • Total production costs are now expected to total $130.0 million to $135.0 million.

7:29 am On the Wires (:WIRES) :

  • Celator Pharmaceuticals (CPXX) announced that data from applying the CombiPlex technology platform to drug combinations incorporating molecularly targeted agents will be presented at the 2015 AACR-NCI-EORTC International Conference
  • Ziptronix, a wholly owned subsidiary of Tessera Technologies (TSRA) entered into a development agreement with Fraunhofer IZM-ASSID. The companies will work together to integrate Ziptronix Direct Bond Interconnect technology into Fraunhofer's 300mm wafer production line
  • Cardiovascular Systems (CSII) enrolled its first 2 patients in its OPTIMIZE, peripheral Orbital Atherectomy System study
  • Francesca's Holdings Corporation (FRAN) appointed Laurie Hummel as Executive Vice President and Chief Merchandising Officer; effective November 30, 2015. Most recently, Hummel served as SVP Divisional Merchandise Manager at Kohl's
  • Alnylam Pharmaceuticals (ALNY) announced that its scientists and collaborators will present results from ongoing Phase 2 open-label extension studies w/ its investigational RNAi therapeutics in development for the treatment of transthyretin-mediated amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis being held November 2-3, 2015 in Paris, France.

7:27 am Independent Bank Q3 EPS $0.22 vs $0.23 two analyst estimate (IBCP) :

7:24 am Armstrong World Industries beats by $0.06, misses on revs; guides FY15 in-line (AWI) :

  • Reports Q3 (Sep) earnings of $0.80 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.74; revenues fell 3.0% year/year to $658.5 mln vs the $675.64 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $2.15-2.35, excluding non-recurring items, vs. $2.27 Capital IQ Consensus Estimate; sees FY15 revs of $2.40-2.45 bln from $2.4-2.5 bln vs. $2.45 bln Capital IQ Consensus Estimate.
  • "Despite pressure from foreign exchange headwinds, we continue to expect to benefit from lower input costs, primarily in our flooring businesses, and are increasing our full year adjusted EBITDA and adjusted EPS guidance at the midpoint."

7:22 am Lancaster Colony beats by $0.10, beats on revs (LANC) :

  • Reports Q1 (Sep) earnings of $1.01 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $0.91; revenues rose 13.1% year/year to $294.1 mln vs the $278.7 mln Capital IQ Consensus. Pricing helped to reduce the impact of the higher egg costs while other ingredient costs were modestly favorable, particularly soybean oil and dairy-based ingredients.

7:22 am LKQ reports EPS in-line, revs in-line; guides FY15 EPS in-line (LKQ) :

  • Reports Q3 (Sep) earnings of $0.33 per share, in-line with the Capital IQ Consensus of $0.33; revenues rose 6.4% year/year to $1.83 bln vs the $1.83 bln Capital IQ Consensus. The Company noted that adjusted diluted earnings per share for the third quarter 2015 would have been $0.34 compared to $0.31 for the third quarter of 2014 after adjusting each of the periods for net losses resulting from restructuring and acquisition related expenses, and the change in fair value of contingent consideration liabilities.
  • Co narrows guidance for FY15, sees EPS of $1.39-1.44 vs. $1.41 Capital IQ Consensus Estimate; sees revenue up 7.0-7.5%, vs. prior range of 7.0-8.5% (consensus +8%).

7:20 am Gaming and Leisure Properties beats by $0.07, misses on revs (GLPI) :

  • Reports Q3 (Sep) funds from operations of $0.69 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.62; revenues rose 0.6% year/year to $147.8 mln vs the $161.77 mln Capital IQ Consensus.

7:20 am NeoGenomics reports EPS in-line, misses slightly on revs; guides FY15 revs to the lower end of prior guidance (NEO) :

  • Reports Q3 (Sep) net of breakeven, in-line with the Capital IQ Consensus of ($0.00); revenues rose 8.2% year/year to $25.13 mln vs the $25.72 mln Capital IQ Consensus.
  • Co issues guidance for FY15, it now sees FY15 revs at the lower end of prior guidance of $100-103 mln vs. $100.9 mln Capital IQ Consensus Estimate.
  • "We are very proud of our laboratory operations teams. During Quarter 3, we reduced Cost per Test in our base business by a significant 12.5% from last year....We are most excited about the pending acquisition of the Clarient business from GE HealthCare that we announced last week. We estimate that this acquisition will more than double the Company's net revenue in 2016...we expect to close the transaction near the end of 2015."

7:19 am Inteliquent beats by $0.01, beats on revs; guides FY15 revs above consensus and prior range (IQNT) :

  • Reports Q3 (Sep) earnings of $0.24 per share, $0.01 better than the two analyst estimate of $0.23; revenues rose 18.0% year/year to $63.71 mln vs the $60.68 mln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees FY15 revs of $245-255 bln vs. $244.94 mln Capital IQ Consensus Estimate, prior range $240-250 mln.

7:19 am Iridium Communications beats by $0.05, beats on revs (IRDM) :

  • Reports Q3 (Sep) earnings of $0.24 per share, $0.05 better than the Capital IQ Consensus of $0.19; revenues fell 1.4% year/year to $106 mln vs the $104.63 mln Capital IQ Consensus.
  • Operational EBITDA for Q3 was $63.8 mln, as compared to $58.4 mln for the prior-year period, representing a year-over-year increase of 9% and an OEBITDA margin of 60%.
  • Co reaffirms the following FY15 guidance: Total service revenue growth between 1% and 3% for the full-year 2015. Full-year 2015 OEBITDA of ~ $230 mln. OEBITDA for 2014 was $216.5 mln.
  • Long Range Outlook: Total service revenue between $420 mln and $465 mln for the full-year 2018, an increase from $309.4 mln for the full-year 2014.

7:18 am MGM Resorts beats by $0.12, reports revs in-line; announces plans to create a REIT (MGM) :

  • Reports Q3 (Sep) earnings of $0.15 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus of $0.03; revenues fell 8.2% year/year to $2.28 bln vs the $2.3 bln Capital IQ Consensus.
  • Net revenue at the Company's wholly owned domestic resorts was $1.6 billion, an increase of 4% compared to the prior year quarter;
  • Rooms revenue at wholly owned domestic resorts increased 8% with an 8% increase in REVPAR (vs. +6% guidance) at the Company's Las Vegas Strip resorts compared to the prior year quarter;
  • The Company's wholly owned domestic resorts earned Adjusted Property EBITDA of $411 million, a 25% increase compared to the prior year quarter;
  • MGM China's net revenue was $529 million and Adjusted EBITDA was $128 million, decreases of 33% and 40%, respectively, compared to the prior year quarter.
  • Co also plans to form a REIT following pressure from an activist.

7:17 am Sherwin-Williams beats by $0.10, misses on revs; guides Q4 EPS in-line (SHW) :

  • Reports Q3 (Sep) earnings of $3.97 per share, $0.10 better than the Capital IQ Consensus of $3.87; revenues rose 0.1% year/year to $3.15 bln vs the $3.24 bln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees EPS of $1.70-1.95 vs. $1.90 Capital IQ Consensus Estimate.
  • "For the fourth quarter, we anticipate our consolidated net sales will be up low single digits compared to last year's fourth quarter. At that anticipated sales level, we estimate diluted net income per common share in the fourth quarter of 2015 to be in the range of $1.70 to $1.95 per share compared to $1.37 per share earned in the fourth quarter of 2014. For the full year 2015, we expect consolidated net sales to increase by a low single digit percentage compared to full year 2014. With annual sales at that level, we are increasing our guidance that diluted net income per common share for 2015 to be in the range of $10.75 to $11.00 per share compared to $8.78 per share earned in 2014."

7:16 am HeartWare misses by $0.79, misses on revs (HTWR) :

  • Reports Q3 (Sep) loss of $1.36 per share, excluding non-recurring items, $0.79 worse than the Capital IQ Consensus of ($0.57); revenues fell 5.0% year/year to $65.2 mln vs the $67.59 mln Capital IQ Consensus.
  • Gross margin percentage declined to 49.4% during the third quarter of 2015, from 65.7% during the second quarter of 2015 and 66.5% in the third quarter of 2014.
  • "In early August, we successfully completed enrollment in the 465-patient ENDURANCE2 destination therapy study of our HVAD System. As a result, we sold 15 units for the destination therapy study in the third quarter of 2015, compared to 62 units sold for this study in the third quarter of 2014. Exclusive of ENDURANCE2 trial units, U.S. unit sales increased by approximately 4% over the third quarter of 2014,"

7:16 am MSCI beats by $0.06, reports revs in-line; issues adjusted EBITDA expense guidance (MSCI) :

  • Reports Q3 (Sep) earnings of $0.60 per share, excluding non-recurring...

More